Week 144 Results of a Phase II, Randomized, Multicenter Trial Assessing the Safety and Efficacy of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)

被引：0

作者：

Hauser, Stephen ^{[1
]}

Li, David ^{[2
]}

Calabresi, Peter ^{[3
]}

O'Connor, Paul ^{[4
]}

Bar-Or, Amit ^{[5
,6
]}

Barkhof, Frederik ^{[7
]}

Sauter, Annette ^{[8
]}

Leppert, David ^{[9
]}

Masterman, Donna ^{[8
]}

Tinbergen, Jeroen ^{[8
]}

Kappos, Ludwig ^{[10
,11
]}

机构：

[1] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA

[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada

[3] Johns Hopkins Univ, Baltimore, MD USA

[4] Univ Toronto, Dept Neurol, Toronto, ON, Canada

[5] McGill Univ, Montreal Neurol Inst & Hosp, Neuroimmunol Unit, Montreal, PQ, Canada

[6] McGill Univ, Montreal Neurol Inst & Hosp, Expt Therapeut Program, Montreal, PQ, Canada

[7] Vrije Univ Amsterdam, Med Ctr, Dept Radiol, Amsterdam, Netherlands

[8] F Hoffmann La Roche Ltd, Basel, Switzerland

[9] PDCN F Hoffmann La Roche, Basel, Switzerland

[10] Univ Basel Hosp, CH-4031 Basel, Switzerland

[11] Univ Basel Hosp, Dept Biomed, CH-4031 Basel, Switzerland

来源：

NEUROLOGY | 2013年 / 80卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

S31004

引用

页数：2

共 50 条

[1] Long-Term Efficacy and Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Week 96 Results of a Phase II, Randomized, Multicenter Trial
Hauser, Stephen
Kappos, Ludwig
Li, David
Calabresi, Peter
O'Connor, Paul
Bar-Or, Amit
Barkhof, Frederik
Wells, Chris
Leppert, David
Glanzman, Robert
Tinbergen, Jeroen
NEUROLOGY, 2012, 78
[2] Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: 48 Week Efficacy and Safety Results of a Phase II Randomized Placebo-Controlled Multicenter Trial
Kappos, Ludwig
Li, David
Calabresi, Peter
O'Connor, Paul
Bar-Or, Amit
Barkhof, Frederik
Yin, Ming
Leppert, David
Glanzman, Robert
Tinbergen, Jeroen
Hauser, Stephen
NEUROLOGY, 2011, 76 (09) : A545 - A545
[3] Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial
Kappos, L.
Li, D.
Calabresi, P.
O'Connor, P.
Bar-Or, A.
Barkhof, F.
Wells, C.
Leppert, D.
Masterman, D.
Tinbergen, J.
Hauser, S. L.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 140 - 141
[4] Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: Week 144 results of a Phase II, randomised, multicentre trial
Kappos, L.
Bar-Or, A.
Sauter, A.
Leppert, D.
Li, D.
Masterman, D.
Barkhof, F.
Tinbergen, J.
O'Connor, P.
Calabresi, P. A.
Hauser, S. L.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (12) : 1875 - 1875
[5] Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial
Kappos, L.
Li, D.
Calabresi, P.
O'Connor, P.
Bar-Or, A.
Barkhof, F.
Yin, M.
Leppert, D.
Glanzmann, R.
Tinbergen, J.
Hauser, S. L.
MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S194 - S195
[6] Ocrelizumab in relapsing-remitting multiple sclerosis: 72-week efficacy and safety results of a phase II, randomised, placebo-controlled, multi-centre trial
Kappos, L.
Li, D.
Calabresi, P.
O'Connor, P.
Bar-Or, A.
Barkhof, F.
Yin, M.
Leppert, D.
Glanzman, R.
Tinbergen, J.
Hauser, S.
JOURNAL OF NEUROLOGY, 2011, 258 : 14 - 14
[7] Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis
Kappos, L.
Li, D.
Calabresi, P.
O'Connor, P.
Bar-Or, A.
Barkhof, F.
Wells, C.
Leppert, D.
Glanzman, R.
Tinbergen, J.
Hauser, S.
JOURNAL OF NEUROLOGY, 2012, 259 : S65 - S65
[8] Comparing the Efficacy and Safety of Natalizumab and Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis and Spinal Lesions
Huntemann, Niklas
Mueller, Marc
Masanneck, Lars
Baumgart, Romy
Axhausen, Franziska
Wolff, Stephanie
Kutsojannis, Bela
Koelsche, Tristan
Korsen, Melanie
Pfeuffer, Steffen
Meuth, Sven
Pawlitzki, Marc
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 90 - 91
[9] A phase II randomized, placebo-controlled, multicenter trial of rituximab in adults with relapsing remitting multiple sclerosis (RRMS)
Hauser, Stephen
Waubant, Emmanuelle
Arnold, Douglas
Vollmer, Timothy
Antel, Jack
Fox, Robert
Bar-Or, Amit
Sarkar, Neena
Langer-Gould, Annette
Panzara, Michael
Smith, Craig
NEUROLOGY, 2007, 68 (12) : A99 - A100
[10] A phase 1, open-label, multicenter study to evaluate the safety and activity of rituximab in adults with relapsing-remitting multiple sclerosis (RRMS): 72 week results
Bar-Or, Amit
Calabresi, Peter
Arnold, Douglas
Markowitz, Clyde
Shafer, Stuart
Kasper, Lloyd
Waubant, Emmanuelle
Gazda, Suzanne
Fox, Robert
Sarkar, Neena
Panzara, Michael
Smith, Craig
NEUROLOGY, 2008, 70 (11) : A119 - A120

← 1 2 3 4 5 →